The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.

The FDA's proposal to use non-animal models for first-in-human trials is a long-term scientific shift. However, competitors like Australia and China achieve faster trial starts now by simply streamlining existing regulatory processes, making them more attractive for biotech companies in the short-term.

The challenge from China in biotech isn't just about their progress; it's a mirror reflecting America's self-inflicted inefficiencies. The U.S. has become too slow for early-stage trials, lagging even Australia, which has one-tenth the population but runs four times as many first-in-human studies.

Biotech CEO Paul Hastings bluntly states that China is "kicking our ass" in clinical trials due to a focused approach, while the U.S. system is strained by an over-reliance on slow, bureaucratic academic centers that fail to enroll patients efficiently.

Long-standing bottlenecks in U.S. first-in-human trials are finally being addressed due to intense competitive pressure from China. This has created a rare sense of urgency among U.S. policymakers, the FDA, and academic centers, forcing them to modernize processes that have been slow for years.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

Since 2016, China has rapidly reformed its systems, moving from a laggard to the global leader in initiating clinical trials. This lead extends beyond simple volume to pioneering completely new therapies, particularly in areas like cell and gene therapy.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.